During the summit, the Torqur team will deliver a scientific presentation, highlighting the company’s progress in the development of topical bimiralisib for actinic keratosis (AK), a common precancerous skin condition with significant unmet medical need.

The presentation will feature recent clinical and translational data supporting the continued development of bimiralisib, a dual pan PI3K/mTOR inhibitor designed to target a key oncogenic signaling pathway involved in the progression of actinic keratosis and cutaneous squamous cell carcinoma. Recent clinical findings demonstrated encouraging field-directed efficacy and favorable tolerability, supporting a differentiated mechanism-driven therapeutic approach.

Alongside the topical bimiralisib program, the oral bimiralisib program is informed by the broader oncology interest in targeting the PI3K/mTOR pathway, one of the most frequently dysregulated pathways in cancer. While many approaches have focused on isoform-selective inhibition, increasing scientific attention is being given to broader pathway inhibition to address pathway complexity and resistance mechanisms, positioning bimiralisib as a differentiated dual PI3K/mTOR inhibitory approach.

Torqur AG will be represented at the summit by Dr. Dana Novac, Chief Medical Officer; Dr. Petra Hillmann, Head of Translational Science; and Dr. Patrick Schnider, Head of Research & Development.

Dana Novac and Petra Hillmann will represent the company as featured speakers during the scientific program.
“Actinic keratosis remains a disease in which patients and physicians continue to need more effective and better-tolerated treatment options. We look forward to presenting the progress of our bimiralisib program and discussing the translational and clinical findings supporting its further development,” said Dana Novac, Chief Medical Officer.